TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02291029
Drug: CFZ533 placebo- Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses of placebo s.c. injection
Study: NCT02291029
Drug: CFZ533 placebo - Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses of placebo intravenous infusion
Study: NCT02488538
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: women will receive oral fluoxetine 20 mg daily
Study: NCT02488538
Drug: Combined oral contraceptives placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
Study: NCT02488538
Drug: Fluoxetine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
Study: NCT04513652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Ophthalmic Solution
Study: NCT03110354
Drug: DS-3201b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
Study: NCT00388648
Drug: mixture of amino and keto acids
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02938572
Drug: NNC0143-0406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c. under the skin)
Study: NCT02935725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00778596
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Study: NCT00778596
Drug: Placebo priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Study: NCT00113100
Drug: Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00253084
Drug: CD-LD IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Study: NCT00697697
Drug: 0.135mg MAP0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study: NCT00697697
Drug: 0.25mg MAP0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study: NCT00037830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per day subcutaneous injection, equal volume as active drug
Study: NCT01153321
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Oral dose od
Study: NCT01153321
Drug: AZD2423 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose od
Study: NCT00457860
Drug: Immunotoxin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04109924
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00089921
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg capsule three times daily for 12 weeks
Study: NCT00089921
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg capsule three times daily for 12 weeks
Study: NCT00089921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules three times daily and one tablet daily
Study: NCT00089921
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet once daily for 12 weeks
Study: NCT02147899
Drug: SYM-1219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02147899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00559910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00900627
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Oral bid
Study: NCT00800553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of placebo for approx. 2 weeks
Study: NCT03597893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasally administrated
Study: NCT04510090
Drug: EP547
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EP547
Study: NCT04510090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03428529
Drug: Capecitabine Oral Product
Normalized name: capecitabine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Capecitabine concomitant to external beam radiotherapy
Study: NCT03428529
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
Study: NCT01405833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV matched placebo
Study: NCT03033225
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo EUS-guided PDT
Study: NCT00002768
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
Study: NCT00643760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00643760
Drug: GEn 1200mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 1200mg/day
Study: NCT00643760
Drug: GEn 2400mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 2400mg/day
Study: NCT00643760
Drug: GEn 3600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 3600mg/day
Study: NCT01491022
Drug: Ampyra first, then Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg po bid for 4 weeks followed by placebo 4 weeks.
Study: NCT01491022
Drug: placebo first, then Ampyra
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03082508
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: as per protocol
Study: NCT02128646
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02974439
Drug: Norvasc Tablets 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
Study: NCT04391998
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet twice daily after meals
Study: NCT00280423
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02741323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.
Study: NCT01549691
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given night before surgery and at awakening, the day of surgery
Study: NCT01637948
Drug: Listerine mouthrinse
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: For six months
Study: NCT00414869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive powder matching NCX-1000
Study: NCT02683109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01451827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT00620282
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
Study: NCT01579500
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of normal saline
Study: NCT00831129
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg daily
Study: NCT00707759
Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d
Study: NCT01038739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g per day
Study: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Study: NCT02160236
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
Study: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Study: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
Study: NCT03796962
Drug: XEN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT03192657
Drug: Calcineurin Inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
Study: NCT03192657
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of steroid can be adjusted according to personal experience of the researcher.
Study: NCT03013400
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is identical in appearance to the ebselen capsules
Study: NCT00003537
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT04020536
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Study: NCT03760445
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg and 10mg capsules, given orally
Study: NCT03760445
Drug: anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg or other strength as locally available given intravenously
Study: NCT03656952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching PF-06700841
Study: NCT02907567
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study drug
Study: NCT02907567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active study drug
Study: NCT01450813
Drug: Saline 0.06 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion x1 prior to laryngoscopy
Study: NCT00589121
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
Study: NCT00653523
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily
Study: NCT00856037
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01625338
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF 400 mg tablet administered orally once daily
Study: NCT00737100
Drug: Placebo Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive placebo matching active drug once daily
Study: NCT00580957
Drug: Blocked
Normalized name: Strepsils Sore Throat and Blocked Nose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
Study: NCT00580957
Drug: Intact
Normalized name: Intact parathyrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
Study: NCT04023396
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Study: NCT01760655
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03248492
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Study: NCT03007303
Drug: Atypical Antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
Study: NCT01719380
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719380
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03713684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT03713684
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Study: NCT01134952
Drug: Mycophenolate to sirolimus switch
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
Study: NCT01055301
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01055301
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00974311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00412841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets identical to atorvastatin 40mg
Study: NCT02071459
Drug: L-Threo DOPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
Study: NCT02071459
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial period (4 weeks) followed by 8 weeks
Study: NCT03671070
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Low dose Boluses
Study: NCT01305200
Drug: supersaturated calcium phosphate rinse
Normalized name: Phos Flur Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinse
Study: NCT01634113
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tiotropium
Study: NCT03671070
Drug: Traditional management of shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency.
Study: NCT03102502
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
Study: NCT01561690
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01403389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Study: NCT00967031
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03511703
Drug: Chemotherapy drugs+Iodized oil
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
Study: NCT06609993
Drug: intravenous rescue opioid analgesia using fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
Study: NCT06609993
Drug: primary treatment of postoperative nausea and vomiting (PONV)
Normalized name: Pepto Nausea
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
Study: NCT06609993
Drug: secondary treatment of postoperative nausea and vomiting (PONV)
Normalized name: Pepto Nausea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
Study: NCT00951561
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg daily
Study: NCT03483077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT03459157
Drug: HIV prevention package including PrEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Study: NCT04657068
Drug: ART0380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
Study: NCT01424163
Drug: Single dose reduced
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (Part A)
Study: NCT01424163
Drug: Single dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (Part A)
Study: NCT01424163
Drug: Multiple Dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3 (Part A)
Study: NCT01424163
Drug: Multiple Dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B
Study: NCT02746432
Drug: Hyper insulinemic euglycemic clamp
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
Study: NCT00535756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02697071
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Study: NCT01994837
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet